CAJ | 학술논문

目的：探讨吉非替尼单药二线治疗非小细胞肺癌的临床疗效及毒副反应。方法经病理学确诊的非小细胞肺癌患者70例(鳞癌30例，腺癌40例)，均给予口服吉非替尼(250 mg/d)，并观察治疗效果及药物毒副反应。结果全组70例患者中， CR 5例、PR 14例、SD 28例、PD 23例，总有效率27.14%，疾病控制率67.14%。腺癌总有效率及疾病控制率高于鳞癌(χ2=5.036、6.994；P=0.024、0.008)。主要毒副反应大多为轻度皮疹、腹泻、疲乏、肝功能异常等。结论吉非替尼二线治疗非小细胞肺癌具有一定疗效，毒副反应也可耐受；对腺癌的疗效明显优于鳞癌。
목적：탐토길비체니단약이선치료비소세포폐암적림상료효급독부반응。방법경병이학학진적비소세포폐암환자70례(린암30례，선암40례)，균급여구복길비체니(250 mg/d)，병관찰치료효과급약물독부반응。결과전조70례환자중， CR 5례、PR 14례、SD 28례、PD 23례，총유효솔27.14%，질병공제솔67.14%。선암총유효솔급질병공제솔고우린암(χ2=5.036、6.994；P=0.024、0.008)。주요독부반응대다위경도피진、복사、피핍、간공능이상등。결론길비체니이선치료비소세포폐암구유일정료효，독부반응야가내수；대선암적료효명현우우린암。
Objective To investigate the clinical efficacy and toxic and adverse effects of gefitinib in the second-line treatment of non-small cell lung cancer. Methods There were 70 cases of non-small cell lung cancer (30 cases of squamous cell carcinoma and 40 cases of adenocarcinoma) given gefitinib through oral administration (250 mg/d), and the clinical efficacy and toxic and adverse effects were observed. Results In the 70 cases, there were 5 cases of complete remission (CR), 14 cases of partial remission (PR), 28 cases of stable disease (SD), and 23 cases of progressive disease (PD). The total effective rate was 27.14%, and the disease control rate was 67.14%. The total effective rate and disease control rate of adenocarcinoma were higher than those of squamous cell carcinoma (χ2=5.036, 6.994;P=0.024, 0.008). The main toxic and adverse effects were mild rash, diarrhea, fatigue, and abnormal liver function. Conclusion Gefitinib is effective in the second-line treatment of non-small cell lung cancer, and its toxic and adverse effects can be tolerated. Its curative effect for adenocarcinoma is obviously better than squamous cell carcinoma.